Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All sleep studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchSleepSleep (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk Hospitalization 15% PASC 23% Sleep for COVID-19  Wang et al.  Prophylaxis Is better sleep beneficial for COVID-19? Prospective study of 68,896 patients in the United Kingdom Lower mortality (p=0.00079) and hospitalization (p<0.0001) c19early.org Wang et al., medRxiv, January 2024 Favors good sleep Favors control

Healthy lifestyle for the prevention of post-COVID-19 multisystem sequelae, hospitalization, and death: a prospective cohort study

Wang et al., medRxiv, doi:10.1101/2024.01.30.24302040
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Sleep for COVID-19
15th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.0000000019 from 15 studies.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
Prospective study of 68,896 UK Biobank participants with COVID-19 showing adherence to a healthy lifestyle prior to infection, characterized by 10 factors including adequate physical activity and sleep, not smoking, and a healthy BMI, was associated with a significantly lower risk of mortality, hospitalization, and post-COVID multisystem sequelae. Risk decreased monotonically for increasing numbers of healthy lifestyle factors from 5-10. Reduced risks were evident across cardiovascular, metabolic, neurologic, respiratory, and other disorders over 210 days following infection, during both acute and post-acute phases, regardless of age, sex, ethnicity, test setting, vaccination status, or SARS-CoV-2 variant.
Study covers exercise, sleep, and diet.
risk of death, 19.0% lower, HR 0.81, p < 0.001, higher quality sleep 50,777, lower quality sleep 18,119, adjusted per study, 7-9 hrs vs. <7 or >9, multivariable.
risk of hospitalization, 15.0% lower, HR 0.85, p < 0.001, higher quality sleep 50,777, lower quality sleep 18,119, adjusted per study, 7-9 hrs vs. <7 or >9, multivariable.
risk of PASC, 23.0% lower, HR 0.77, p < 0.001, higher quality sleep 50,777, lower quality sleep 18,119, adjusted per study, 7-9 hrs vs. <7 or >9, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wang et al., 31 Jan 2024, prospective, United Kingdom, preprint, 10 authors.
This PaperSleepAll
Healthy lifestyle for the prevention of post-COVID-19 multisystem sequelae, hospitalization, and death: a prospective cohort study
BSMed, MSc Yunhe Wang, PhD Binbin Su, PhD Marta Alcalde-Herraiz, PhD Nicola L Barclay, PhD Yaohua Tian, Chunxiao Li, PhD Nicholas J Wareham, PhD Roger Paredes, PhD Junqing Xie, Daniel Prieto-Alhambra
doi:10.1101/2024.01.30.24302040
Background Post-COVID complications are emerging as a global public health crisis. Effective prevention strategies are needed to inform patients, clinicians and policy makers, and to reduce their cumulative burden. We aimed to investigate whether a habitual healthy lifestyle predated pandemic is associated with lower risks of multisystem sequelae and other adverse outcomes of COVID-19, and whether the potential protective effects are independent of pre-existing comorbidities. Methods The prospective population-based cohort study enrolled participants with SARS-CoV-2 infection confirmed by a positive polymerase chain reaction test result between March 1, 2020, and March 1, 2022. Participants with no history of the related outcome one year before infection were included and followed up for 210 days. Exposures included ten modifiable healthy lifestyle factors including past or never smoking, moderate alcohol intake (≤4 times week), body mass index <30 kg/m 2 , at least 150 minutes of moderate or 75 minutes of vigorous physical activity per week, less sedentary time (<4 hours per day), healthy sleep duration (7-9 hours per day), adequate intake of fruit and vegetables (≥400 g/day), adequate oily fish intake (≥1 portion/week), moderate intake of red meat (≤4 portions week) and processed meat (≤4 portions week). Outcomes included multisystem COVID-19 sequelae (consisting of 75 diseases/symptoms in 10 organ systems), death, and hospital admission following SARS-CoV-2 infection, confirmed by hospital inpatient and death records. Risk was reported in relative scale (hazard ratio [HR]) and absolute scale (absolute risk reduction [ARR]) during both the acute (the first 30 days) and post-acute (30-210 days) phases of infection using Cox models. Findings A total of 68,896 participants (mean [SD] age, 66.6 [8.4]; 32,098 women [46.6%]) with COVID-19 were included. A favorable lifestyle (6-10 healthy lifestyle factors; 46.4%) was associated with a 36% lower risk of multisystem sequelae of COVID-19 (HR, 0.64; 95% CI, 0.58-0.69; ARR, 7.08%; 95% CI, 5.98-8.09), compared with unfavorable lifestyle (0-4 factors; 12.3%). Risk reductions were observed across all 10 prespecified organ systems including cardiovascular, coagulation, metabolic and endocrine, gastrointestinal, kidney, mental health, musculoskeletal, neurologic, and respiratory disorders, and general symptoms of fatigue and malaise. This beneficial effect was largely attributable to direct effects of healthy lifestyle, with mediation proportion ranging from 44% to 93% across organ systems. A favorable lifestyle was also associated with lower risk of post-COVID death (HR, 0.59; 95% CI, 0.52-0.66; ARR, 1.99%; 95% CI, 1.61-2.32) and hospitalization (HR, 0.78; 95% CI, 0.73-0.84; ARR, 6.14%; 95% CI, 4.48-7.68). These associations were observed after accounting for potential misclassification of lifestyle factors, and during acute and post-acute infection, in those tested positive in the hospital and..
Author contributions Drs Wang and Xie had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses. Concept and design: Wang and Xie. Acquisition, analysis, or interpretation of data: Wang, Xie, and Prieto-Alhambra. Drafting of the manuscript: Wang. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: Xie. Obtained funding: Prieto-Alhambra. Administrative, technical, or material support: Prieto-Alhambra. Supervision: Nicholas J. Wareham and Prieto-Alhambra. Competing interests Dr Prieto-Alhambra's department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, A, qualitative sensitivity analyses. B, quantative sensitivity analysis accounting for potential misclassification of lifestyle factors over time. a Odds ratios were used to quantify associations and assumed a sensitivity and specificity of 90% for each lifestyle component.
References
Ahmadi, Huang, Inan-Eroglu, Hamer, Stamatakis, Lifestyle risk factors and infectious disease mortality, including COVID-19, among middle aged and older adults: Evidence from a community-based cohort study in the United Kingdom, Brain, behavior, and immunity
Al-Aly, Agarwal, Alwan, Luyckx, Long COVID: long-term health outcomes and implications for policy and research, Nature Reviews Nephrology
Al-Aly, Bowe, Xie, Long COVID after breakthrough SARS-CoV-2 infection, Nature medicine
Al-Aly, Xie, Bowe, High-dimensional characterization of post-acute sequelae of COVID-19, Nature
Armstrong, Rudkin, Allen, Dynamic linkage of COVID-19 test results between Public Health England's second generation surveillance system and UK Biobank, Microbial genomics
Ballouz, Menges, Anagnostopoulos, Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study
Bowe, Xie, Al-Aly, Postacute sequelae of COVID-19 at 2 years, Nature Medicine
Bowe, Xie, Xu, Al-Aly, Kidney outcomes in long COVID, Journal of the American Society of Nephrology
Bycroft, Freeman, Petkova, The UK Biobank resource with deep phenotyping and genomic data, Nature
Cashin, Mcauley, Vanderweele, Lee, Understanding how health interventions or exposures produce their effects using mediation analysis, BMJ (Clinical Research, doi:10.1136/bmj-2022-071757
Daugherty, Guo, Heath, Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study, Bmj
Davis, Mccorkell, Vogel, Topol, Long COVID: major findings, mechanisms and recommendations, Nature Reviews Microbiology
Denaxas, Gonzalez-Izquierdo, Direk, UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER, Journal of the American Medical Informatics Association
Firth, Solmi, Wootton, A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders, World psychiatry
Florencio, Fernández-De-Las-Peñas, Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00159-X50
Foster, Celis-Morales, Nicholl, The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort, The Lancet Public Health
Ghouse, Tragante, Ahlberg, Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism, Nature Genetics
Greenhalgh, Sivan, Delaney, Evans, Milne, Long covid-an update for primary care
Gregson, Kaptoge, Bolton, Cardiovascular risk factors associated with venous thromboembolism, JAMA cardiology
Hamer, Kivimäki, Gale, Batty, Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: A community-based cohort study of 387,109 adults in UK, Brain, behavior, and immunity
Hanson, Abbafati, Aerts, Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021, Jama
Kuan, Denaxas, Gonzalez-Izquierdo, A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service, The Lancet Digital Health
Lam, Wong, Zhang, Long-term post-acute sequelae of COVID-19 infection: a retrospective, multidatabase cohort study in Hong Kong and the UK, EClinicalMedicine, doi:10.1016/j.eclinm.2023.102000
Ledford, Long-COVID treatments: why the world is still waiting, Nature
Lee, Cashin, Lamb, A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies: The AGReMA Statement, JAMA, doi:10.1001/jama.2021.14075
Loef, Walach, The combined effects of healthy lifestyle behaviors on all cause mortality: a systematic review and meta-analysis, Preventive medicine
Luo, Liang, Wong, Schooling, Yeung, Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies, Int J Epidemiol, doi:10.1093/ije/dyac076
Martí, Raivo, The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort analyses of data from the UK, Spain, and Estonia, Lancet Respir Med
Munblit, Nicholson, Akrami, A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study, Lancet Respir Med, doi:10.1016/s2213-2600(22)00169-2
Nhs, NHS advice about healthy living, including eating a balanced diet, healthy weight, exercise, quitting smoking and drinking less alcohol
Nyberg, Singh-Manoux, Pentti, Association of healthy lifestyle with years lived without major chronic diseases, JAMA internal medicine
Parotto, Gyöngyösi, Howe, Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations, Lancet Respir Med, doi:10.1016/s2213-2600(23)00239-4
Patnode, Redmond, Iacocca, Henninger, Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the us preventive services task force, Jama
Perricone, Versini, Ben-Ami, Smoke and autoimmunity: The fire behind the disease, Autoimmunity reviews
Salman, Vishnubala, Feuvre, Returning to physical activity after covid-19
Shaffer, Lots of long COVID treatment leads, but few are proven, Proceedings of the National Academy of Sciences
Sharif, Watad, Bragazzi, Lichtbroun, Amital et al., Physical activity and autoimmune diseases: Get moving and manage the disease, Autoimmunity reviews
Smith, Noble, Noble, Wright, Mclennan et al., The English indices of deprivation 2015
Tsampasian, Elghazaly, Chattopadhyay, Risk factors associated with Post-COVID-19 condition: a systematic review and meta-analysis, JAMA Internal Medicine
Vos, Lim, Abbafati, Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet
Wang, Li, Yue, Adherence to healthy lifestyle prior to infection and risk of post-COVID-19 condition, JAMA Internal Medicine
Xie, Al-Aly, Risks and burdens of incident diabetes in long COVID: a cohort study, The lancet Diabetes & endocrinology
Xie, Choi, Al-Aly, Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition, JAMA Internal Medicine
Xie, Choi, Al-Aly, Molnupiravir and risk of post-acute sequelae of covid-19: cohort study
Xie, Xu, Al-Aly, Risks of mental health outcomes in people with covid-19: cohort study
Xie, Xu, Bowe, Al-Aly, Long-term cardiovascular outcomes of COVID-19, Nature medicine
Xu, Xie, Al-Aly, Long-term gastrointestinal outcomes of COVID-19, Nature communications
Xu, Xie, Al-Aly, Long-term neurologic outcomes of COVID-19, Nature medicine
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit